| Exclusion Criteria: | 1) Renal insufficiency, serum creatinine levels of more than 2 mg/dl.
2) Concomitant therapy that includes corticosteroids or other chemotherapy that is or may be active against myeloma.
3) Peripheral neuropathy of Grade 3 or greater assessed by a directed neurologic examination, including light touch, pinprick, proprioception, and deep tendon reflexes (DTR) of the upper and lower extremities; and questioning for symptoms of paresthesia and numbness (FACT/GOG-Ntx).
4) Patients with evidence of mucosal or internal bleeding.
5) Patients with a platelet count of < 50,000 cells/mm3.
6) ANC of less than 1000 cells/mm3.
7) ALT or AST levels equal or more than 2 times the upper limit of normal (ULN).
8) Any condition which, in the opinion of the PI, places the patient at unacceptable risk if he/she were to participate in the study.
9) Clinically relevant active infection or serious co-morbid medical conditions.
10) Prior malignancy (within the last 3 years) except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for at least 3 years.
11) If WCBP, pregnant, lactating, or not using adequate contraception.
12) As atiprimod is a potent inhibitor of CYP2D6, patients taking drugs that are substrates of 2D6 (e.g. beta blockers, antidepressants, and antipsychotics; see Appendix H) will be excluded from the study.
13) Patients with nonsecretory myeloma. |